No full-text available
To read the full-text of this research,
you can request a copy directly from the authors.
[Clinical research of xinganbao capsule on the treatment of chronic hepatitis B liver fibrosis]
Abstract
To explore the effects of Xinganbao Capsule (Cordyceps Sinensis) on the chronic hepatitis B liver fibrosis.
Sixty patients with chronic hepatitis B were randomly assigned to the trail group (40 cases) and the control group (20 cases). The trail group was treated with Xinganbao Capsule, 8 capsules each time, three times a day. The control group was given Heluo Shugan Tablet, 5 pills each time, thrice daily. Six months consisted of one therapeutic course. The liver function, four indicators of serum fibrosis, liver histology, and other items were detected.
Xinganbao Capsule could reduce serum ALT and AST levels, serum HA, PC-III and LN levels (all P<0.05), showing statistical difference when compared with before treatment. The HA and LN levels decreased more significantly in the control group when compared with before treatment (P<0.05). Totally 21 patients (53% of the recruited cases) in the trial group completed the liver biopsy twice. After treated with Xinganbao Capsule, 81% patients (17/21) had decreased liver inflammation 1 grade or more, 52% patients (11/21) had decreased fibrosis staging one or more, and 33% (7/21) patients had no change in fibrosis.
Xinganbao Capsule could improve the liver function, reduce liver inflammation, and fight against hepatic fibrosis.
... In traditional Chinese medicine practice, the therapeutic effects reported for O. sinensis are due to contribution of multiple components. There exist extensive reviews on clinical aspects of O. sinensis (Zhu et al. 1998a,b, Holliday 2008, Li & Yang 2009, Wang et al. 2012b) as well as on activity of extracts (Lin & Li 2011). In previous review (Shrestha et al. 2012) we provided overview of compounds reported for O. sinensis. ...
Yarsagumba (Ophiocordyceps sinensis (Berk.) Sung et al.) is a well-known entomogenous fungus native to alpine nival terrain of trans-Himalaya and Tibetan Plateau. The traditional use of O. sinensis in Ayurvedic medicine as well as in traditional Chinese medicine for range of human health requirements with well documented evidences are themselves testimony of its value. It is regarded as winter worm, summer grass due to its association with Thitarodes (Hepialus) larvae. The extremities of habitat condition and endurance of fungus to sustain adversaries by production of metabolites has led to unique profile of metabolites including nucleosides, proteins and nitrogenous compounds, polysaccharides, sterols, fatty acids and their derivatives, as well as some vitamins and inorganics. There are wide ranges of biological activities that have been reported from O. sinensis including anti-inflammatory, antioxidant, anti-tumor, anti-metastatic, immunomodulatory, antimicrobial, insecticidal, hypolipidaemic, hypoglycemic, antiageing, lipolytic, neuroprotective, renoprotective effects, etc. Although several components can be responsible for activity of compounds, understanding ultimate compounds which fit with biomolecular target is crucial to combat diseases and development of new class of effective drugs. In this review a concise evaluation of pharmacological activities of metabolites reported for O. sinensis are done to provide insight into its biologically active components.
The human uses of mushrooms and cultured mycelium products for nutrition and medicine are detailed and supported by available human studies, which in many cases are clinical trials published in peer-reviewed journals. The major medically active immunomodulating compounds in the cell walls-chitin, beta-glucans, and glycoproteins, as well as lower weight molecules-nitrogen-containing compounds, phenolics, and terpenes-are discussed in relation to their current clinical uses. The nutritional content and foods derived from mushrooms, particularly related to their medical benefits, are discussed. High-quality major nutrients such as the high amounts of complete protein and prebiotic fibers found in edible and medicinal fungi and their products are presented. Mushrooms contain the highest amount of valuable medicinal fiber, while dried fruiting bodies of some fungi have up to 80% prebiotic fiber. These fibers are particularly complex and are not broken down in the upper gut, so they can diversify the microbiome and increase the most beneficial species, leading to better immune regulation and increasing normalizing levels of crucial neurotransmitters like serotonin and dopamine. Since the growth of medicinal mushroom products is expanding rapidly worldwide, attention is placed on reviewing important aspects of mushroom and mycelium cultivation and quality issues relating to adulteration, substitution, and purity and for maximizing medicinal potency. Common questions surrounding medicinal mushroom products in the marketplace, particularly the healing potential of fungal mycelium compared with fruiting bodies, extraction methods, and the use of fillers in products, are all explored, and many points are supported by the literature.
Medicinal plants are fast becoming a ready source of antiviral agents without the various limitations associated with synthetic drugs like viral resistance and exorbitant price ranges beyond the reach of 80% of the world population. Several studies have reported that plant metabolites can be used against a variety of infections caused by viruses. Some medicinal plants have been demonstrated to have an improved outcome in the treatment of emerging and re‐emerging viral infections. Hepatitis virus (HV) is responsible for billions of cases of liver infection worldwide and causes severe and frequently transmittable liver diseases. The drugs available in the market for the treatment of hepatitis infections are not sufficiently available and also cause undesirable effects in patients suffering from HV infection. Therefore, the exploration and use of plants as sources of medicines to treat the infection is of utmost importance. Medicinal plants synthesize and preserve a variety of biochemical products possessing potential therapeutic index, aiding elimination, and or inhibition of viruses. Each plant contains a priceless pool of active ingredients that could help in the production of pharmaceutical‐grade metabolites. As researchers and pharmaceutical establishments are striving to discover appropriate alternative inhibitors of the HV life cycle, it is important to document thenumerous potentially useful medicinal plants and herbs evaluated or waiting to be evaluated for anti‐HV activities. This review illustrates the description of medicinal plants, family, active ingredients, plant parts, and extracts used to treat HV and their mechanisms of action.
In the present study, 101 sphingolipids in wild Cordyceps and its five mycelia were quantitatively profiled by using a fully validated UHPLC-MS method. The results revealed that a general rank order for the abundance of different classes of sphingolipids in wild Cordyceps and its mycelia is sphingoid bases/ceramides > phosphosphingolipids > glycosphingolipids. However, remarkable sphingolipid differences between wild Cordyceps and its mycelia were observed. One is that sphingoid base is the dominant sphingolipid in wild Cordyceps, whereas ceramide is the major sphingolipid in mycelia. Another difference is that the abundance of sphingomyelins in wild Cordyceps is almost 10-folds higher than those in most mycelia. The third one is that mycelia contain more inositol phosphorylceramides and glycosphingolipids than wild Cordyceps. Multivariate analysis was further employed to visualize the difference among wild Cordyceps and different mycelia, leading to the identification of respective sphingolipids as potential chemical markers for the differentiation of wild Cordyceps and its related mycelia. This study represents the first report on the quantitative profiling of sphingolipids in wild Cordyceps and its related mycelia, which provided comprehensive chemical evidence for the quality control and rational utilization of wild Cordyceps and its mycelia.
Herbal traditional Chinese medicine (TCM) is used to treat several ailments, but its efficiency is poorly documented and hence debated, as opposed to modern medicine commonly providing effective therapies. The aim of this review article is to present a practical reference guide on the role of herbal TCM in managing gastrointestinal disorders, supported by systematic reviews and evidence based trials. A literature search using herbal TCM combined with terms for gastrointestinal disorders in PubMed and the Cochrane database identified publications of herbal TCM trials. Results were analyzed for study type, inclusion criteria, and outcome parameters. Quality of placebo controlled, randomized, double-blind clinical trials was poor, mostly neglecting stringent evidence based diagnostic and therapeutic criteria. Accordingly, appropriate Cochrane reviews and meta-analyses were limited and failed to support valid, clinically relevant evidence based efficiency of herbal TCM in gastrointestinal diseases, including gastroesophageal reflux disease, gastric or duodenal ulcer, dyspepsia, irritable bowel syndrome, ulcerative colitis, and Crohn's disease. In conclusion, the use of herbal TCM to treat various diseases has an interesting philosophical background with a long history, but it received increasing skepticism due to the lack of evidence based efficiency as shown by high quality trials; this has now been summarized for gastrointestinal disorders, with TCM not recommended for most gastrointestinal diseases. Future studies should focus on placebo controlled, randomized, double-blind clinical trials, herbal product quality and standard criteria for diagnosis, treatment, outcome, and assessment of adverse herb reactions. This approach will provide figures of risk/benefit profiles that hopefully are positive for at least some treatment modalities of herbal TCM. Proponents of modern herbal TCM best face these promising challenges of pragmatic modern medicine by bridging the gap between the two medicinal cultures.
Ophiocordyceps sinensis (Berk.) Sung et al. is popularly known as Yarsagumba (winter worm summer grass) in Nepal. It is a well-known entomogenous fungus distributed in alpine nival zone of trans-Himalayas and Tibetan Plateau. Its occurrence in extreme biological niche and cohabitation with insect [Thitarodes (Hepialus)] larvae has led to unique assemblage of metabolites including proteins and nitrogenous compounds, polysaccharides, sterols, nucleosides, fatty acids and their derivatives, vitamins and inorganics. In traditional Chinese medicine, it is one of the most trusted main ingredients for several preparations of remedy from wide range of human health conditions. Several biological activities from O. sinensis have been reported that include anti-inflammatory, antioxidant, antitumor, anti-metastatic, immunomodulatory, antimicrobial, insecticidal, hypolipidaemic, hypoglycemic, anti-ageing, lipolytic, neuroprotective, renoprotective effects, etc. The chemical constituents and their pharmacological uses are reviewed here highlighting the potentiality of this highly esteemed traditional Himalayan medicine.
ResearchGate has not been able to resolve any references for this publication.